BEKE-W
02423
MEITUAN-W
03690
JD-SW
09618
4
XIAOMI-W
01810
5
BILIBILI-W
09626
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | ---- | ---- | -0.78%15.62B | ---- | ---- | ---- | 6.54%15.75B | ---- | -9.41%28.39B | ---- |
Special items of operating revenue | ---- | 5.34%34.93B | ---- | -12.12%9.86B | ---- | -2.42%33.16B | ---- | 17.05%11.22B | ---- | 7.01%33.98B |
Operating income | 5.13%35.37B | 5.34%34.93B | -0.78%15.62B | -12.12%9.86B | 18.49%33.64B | -2.42%33.16B | 6.54%15.75B | 17.05%11.22B | -9.41%28.39B | 7.01%33.98B |
Operating expenses | ||||||||||
Gross profit | ||||||||||
Administrative expenses | ---- | -7.06%-8.25B | ---- | 5.97%-2.39B | ---- | -6.94%-7.71B | ---- | -21.14%-2.55B | ---- | -0.92%-7.21B |
Employee expense | ---- | ---- | -0.13%-3.58B | ---- | ---- | ---- | -6.17%-3.57B | ---- | -1.22%-7.13B | ---- |
Depreciation and amortization | ---- | ---- | -8.39%-576.02M | ---- | ---- | ---- | -17.28%-531.43M | ---- | -17.50%-970.42M | ---- |
Impairment and provision | ---- | 20.77%156.78M | -87.99%-51.96M | 732.74%126.37M | ---- | 155.85%129.82M | 45.69%-27.64M | 84.80%-19.97M | 169.37%12.06M | -574.25%-232.44M |
-Other impairment is provision | ---- | 20.77%156.78M | -87.99%-51.96M | 732.74%126.37M | ---- | 155.85%129.82M | 45.69%-27.64M | 84.80%-19.97M | 169.37%12.06M | -574.25%-232.44M |
Operating interest expense | ---- | -2.19%-7.84B | -3.69%-5.28B | -4.89%-2.65B | ---- | -14.52%-7.68B | -15.20%-5.09B | -12.21%-2.53B | -12.11%-9.13B | -18.59%-6.7B |
Special items of operating profit | ---- | -4.69%-11.51B | -16.69%-1.58B | 10.98%-3.13B | ---- | 12.20%-10.99B | 8.92%-1.36B | -4.65%-3.52B | -24.90%-3.21B | -30.94%-12.52B |
Operating profit | 31.72%10.82B | 8.72%7.39B | -11.83%4.55B | -30.64%1.79B | 3.09%8.22B | -5.78%6.8B | 3.30%5.16B | 51.02%2.57B | -37.46%7.97B | -22.68%7.22B |
Share of profit from joint venture company | ---- | ---- | -38.56%-10.04M | ---- | ---- | ---- | -3,970.79%-7.25M | ---- | -98.13%872K | ---- |
Special items of earning before tax | ---- | 111.90%8.75M | ---- | 30.78%-8.85M | ---- | -1,010.51%-73.59M | ---- | -245.70%-12.79M | ---- | 110.20%8.08M |
Earning before tax | 32.94%10.81B | 10.03%7.4B | -11.91%4.54B | -30.64%1.78B | 2.04%8.13B | -6.90%6.73B | 3.16%5.16B | 49.50%2.56B | -37.68%7.97B | -21.93%7.23B |
Tax | ---- | -255.37%-437.61M | 28.83%-154.31M | 53.56%-145.3M | ---- | 84.30%-123.14M | 67.68%-216.8M | -102.99%-312.91M | 91.10%-202.39M | 56.07%-784.14M |
After-tax profit from continuing operations | 5.46%6.96B | -11.16%4.39B | -27.45%1.63B | 2.52%6.6B | 14.14%4.94B | 44.22%2.25B | -26.13%7.77B | -13.77%6.44B | ||
Earning after tax | 5.46%6.96B | -11.16%4.39B | -27.45%1.63B | 2.52%6.6B | 14.14%4.94B | 44.22%2.25B | -26.13%7.77B | -13.77%6.44B | ||
Minority profit | ---- | 157.42%300.09K | 10.58%230K | 138.95%94.82K | ---- | -81.44%116.58K | -69.05%208K | -2,882.26%-243.44K | -98.93%932K | -99.09%628.24K |
Profit attributable to shareholders | 28.62%10.13B | 5.46%6.96B | -11.16%4.39B | -27.46%1.63B | 1.43%7.88B | 2.53%6.6B | 14.15%4.94B | 44.23%2.25B | -25.53%7.77B | -12.97%6.44B |
Basic earnings per share | 22.39%0.82 | -8.33%0.55 | -22.22%0.35 | -42.86%0.12 | -4.29%0.67 | 1.69%0.6 | 15.38%0.45 | 50.00%0.21 | -27.84%0.7 | -14.49%0.59 |
Diluted earnings per share | -3.51%0.55 | -18.60%0.35 | -36.84%0.12 | 1.79%0.57 | 13.16%0.43 | 35.71%0.19 | -30.93%0.67 | -18.84%0.56 | ||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | IAS | CAS (2007) | CAS (2007) | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.